. 2017 Jul 4;17(9):1–106.

Table 26:

Population Estimates for Budget Impact Analysis of the LAAC Device, 2016–2020

Population	Year					Source
Population	2016	2017	2018	2019	2020	Source
NVAF at risk (CHA2DS2VASc ≥ 2)	171,848	176,917	182,044	187,229	192,472	Calculation^a
Absolute contraindications to OACs	3,712	3,821	3,932	4,044	4,157	Steinberg, 2015⁷⁸
Relative contraindications to OACs	80,234	82,601	84,995	87,416	89,864	Steinberg, 2015⁷⁸

Abbreviations: CHADS₂DS₂VASc, Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, Stroke or transient ischemic attack symptoms previously (2 points), Vascular disease, Age 65–74 years, Sex category; LAAC device, left atrial appendage closure device with delivery system; NVAF, nonvalvular atrial fibrillation; OAC, oral anticoagulant.

Calculated based on Ontario population estimates⁸⁶ and atrial fibrillation prevalence estimates⁸⁷ assuming that 90% of atrial fibrillation cases are nonvalvular⁸⁸ and 72% of patients are at risk of stroke.³⁷